Clinical Trial Update: Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating firmonertinib versus platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with EGFR mutatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Firmonertinib (firmonertinib)
• Platinum-based chemotherapy (platinum-based chemotherapy)

Snippet

Sponsor: Allist Pharmaceuticals, Inc. | Conditions: EGFR, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 3 | Status: RECRUITING